Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2013

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or CompaniesTable of ContentsTable of Contents 2List of Tables 4List of Figures 6Introduction 7Inflammatory Bowel Disease 7Report Guidance 7Clinical Trials by Region 8Clinical Trials by Country 9Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11Top Five Countries Contributing to Clinical Trials in Europe 12Top Countries Contributing to Clinical Trials in North America 13Top Countries Contributing to Clinical Trials in Middle East and Africa 14Top Countries Contributing to Clinical Trials in Central and South America 15Clinical Trials by BRIC Nations 16Clinical Trials by G7 Nations 17Clinical Trials in G7 Nations by Trial Status 18Clinical Trials by E7 Nations 19Clinical Trials in E7 Nations by Trial Status 20Clinical Trials by Phase 21In Progress Trials by Phase 22Clinical Trials by Trial Status 23Unaccomplished Trials of Inflammatory Bowel Disease 24 Subjects Recruited Over a Period of Time 32Prominent Sponsors 33Top Companies Participating in Inflammatory Bowel Disease Therapeutics Clinical Trials 35Prominent Drug Comparison 37Clinical Trial Profiles 38Clinical Trial Overview of Top Companies 38AbbVie Inc. 38Clinical Trial Overview of AbbVie Inc. 38UCB S.A. 40Clinical Trial Overview of UCB S.A. 40Pfizer Inc. 42Clinical Trial Overview of Pfizer Inc. 42GlaxoSmithKline plc 43Clinical Trial Overview of GlaxoSmithKline plc 43Merck & Co., Inc. 44Clinical Trial Overview of Merck & Co., Inc. 44Ferring Pharmaceuticals, Inc. 45Clinical Trial Overview of Ferring Pharmaceuticals, Inc. 45Alvine Pharmaceuticals, Inc. 46Clinical Trial Overview of Alvine Pharmaceuticals, Inc. try these guys out http://www.marketwatch.com/story/inflammatory-bowel-disease-global-clinical-trials-review-h2-2013-2013-09-12





Inflammatory bowel disease in Aussies tipped to rise





Gastroenterologist Dr Greg Moore says at the moment, access to appropriate treatment is inconsistent, and patients usually only see specialists when the problem flares. But relapses are unpredictable and failing to treat IBD when its active can lead to prolonged exposure to medications, adverse side effects, potentially invasive surgery or even death. Dr Moore says government funding for IBD nurses will help ensure patients are treated sooner, avoiding unnecessary surgeries, hospital stays and pain. "If we have specialist IBD nurses, they're readily accessible and can act as a point of triage so we can get patients in that need to be seen urgently and nip problems in the bud," he said. The cause of IBD is unknown, but it is more common in developed countries and possibly to do with hygienic living or diet. Dr Moore says GPs have poor knowledge of the condition and there is no permanent source of government funding for IBD nurses. "IBD ticks all boxes for a chronic condition. It has elements that are preventable, keeping people out of hospital and improving productivity, yet we can't seem to attract funding or interest," he says. INFLAMMATORY BOWEL DISEASE FACTS * More than 75,000 Australians have Crohn's disease or ulcerative colitis, collectively known as inflammatory bowel disease (IBD). * The chronic disease affects about one in 250 Australians aged 5-49. * Australian has one of the highest rates of IBD in the world and each year more young people are being diagnosed. * The number of Australians with IBD is expected to rise dramatically within the next decade to 100,000. * Research estimates national total hospital costs for IBD are about $100 million a year. * Crohn's disease is incurable and linked to a 47 per cent increase in mortality risk. * Ulcerative colitis is only curable through radical surgery. more helpful hints http://www.news.com.au/lifestyle/health/bowel-disease-tipped-to-rise/story-fneuzlbd-1226635666964